Retrovirus conference report: three new agents to the rescue.
Gilden
D
D
D019380:Anti-HIV Agents; D002219:Carbamates; D003226:Congresses as Topic; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D000077560:Enfuvirtide; D005663:Furans; D015700:HIV Envelope Protein gp41; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D061466:Lopinavir; D010446:Peptide Fragments; D011744:Pyrimidinones / Q000627:therapeutic use*; D016879:Salvage Therapy; D013449:Sulfonamides / Q000627:therapeutic use*; D019562:Viral Load; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D002219:Carbamates; D015507:Drugs, Investigational; D005663:Furans; D015700:HIV Envelope Protein gp41; D017320:HIV Protease Inhibitors; D010446:Peptide Fragments; D011744:Pyrimidinones; D013449:Sulfonamides; D000077560:Enfuvirtide; D061466:Lopinavir; C095108:amprenavir